A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets

Exclusion criteria

• ✕. NYHA class ≥2 heart failure;
• ✕. unstable angina;
• ✕. myocardial infarction within the past 1 year;
• ✕. clinically significant supraventricular or ventricular arrhythmia requiring treatment/intervention;
• ✕. QTc \>450 ms (male) or QTc \>470 ms (female). Coagulation abnormalities (INR \>2.0, PT \>16 seconds), bleeding diathesis, or current use of thrombolytic/anticoagulant therapy (prophylactic low-dose aspirin or low-molecular-weight heparin is permitted).